Have a personal or library account? Click to login
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients Cover

Rosuvastatin effects on the HDL proteome in hyperlipidemic patients

Acta Pharmaceutica
Volume 73 (2023): Issue 3 (September 2023)
By: Ana Vavlukis,  Kristina Mladenovska,  Katarina Davalieva,  Marija Vavlukis and  Aleksandar Dimovski  
Open Access
|Sep 2023

Authors

Ana Vavlukis

ana.vavlukis@gmail.com

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

Kristina Mladenovska

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

Katarina Davalieva

Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology „Georgi D. Efremov“, Skopje, RN Macedonia

Marija Vavlukis

University Ss Cyril and Methodius Faculty of Medicine, Skopje, RN Macedonia

Aleksandar Dimovski

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia
Macedonian Academy of Sciences and Arts, Research Center for Genetic Engineering and Biotechnology „Georgi D. Efremov“, Skopje, RN Macedonia
DOI: https://doi.org/10.2478/acph-2023-0034 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 363 - 384
Accepted on: Aug 7, 2023
Published on: Sep 14, 2023
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
proteomics,
high-density lipoprotein,
rosuvastatin,
Profilin-1,
phospholipid transfer protein,
platelet factor 4 variant
Related subjects:
Pharmacy,
Pharmacy, other

© 2023 Ana Vavlukis, Kristina Mladenovska, Katarina Davalieva, Marija Vavlukis, Aleksandar Dimovski, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 73 (2023): Issue 3 (September 2023)Next article